Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression

Nevenka Ridova a, Sanja Trajkova a, Biljana Chonevska b, Zlate Stojanoski a, Martin Ivanovski a, Marija Popova-Labachevska a, Simona Stojanovska-Jakimovska a, Venko Filipche c, Aspazija Sofijanova d, Irina Panovska-Stavridis a, * a Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, University Clinic for Hematology, 1000 Skopje, Republic of North Macedonia b Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, University Clinic for Neurosurgery, 1000 Skopje, Republic of North Macedonia c Acibadem Sistina Hospital, 1000 Skopje, Republic of North Macedonia d Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, University Clinic for Pediatric Diseases, 1000 Skopje, Republic of North Macedonia

ARTICLE INFO
Keywords:
Gaucher disease
Mutations
Phenotypic profile
Genetic-phenotypic correlations
Macedonian population

ABSTRACT
The majority of Gaucher Disease (GD) cases result from pathologic mutations in the GBA1 gene. A rich mutational spectrum of about 500 identified variants has been recognized. The disease is characterized by phenotypic diversity. Data regarding the genotype-phenotype correlation are scanty and inconclusive. Here, we summarize the genetic and phenotypic “portraits” of 14 patients with GD type 1 in the Republic of North Macedonia, 4 of Macedonian and 10 of Albanian origin. Altogether, 6 variants were detected, compounding 6 different genotypes. All genotypes contained the N370S variant, which was detected with an overall prevalence of 60.7%. Other frequent variants included the 1263del55 deletion and the double mutant allele D409H;H255Q, each with a prevalence of 14.2%. We detected two rare mutations: W92* - a pathogenic nonsense mutation and D399N – a single nucleotide variant of uncertain pathogenicity. The most common genotypes were N370S/1263del55 and H255Q/D409H/N370S, both present in 4/14 patients, followed by N370S homozygosity (3/14). Splenomegaly was the most common clinical manifestation, identified in all patients. Hepatomegaly was less frequent and was present in 50% of cases. Thrombocytopenia was present in 9/14, while half of the patients had anemia. Bone pathology was demonstrated in 8 patients. Patients with different genotypes displayed a high degree of phenotypic heterogeneity, suggesting that the other allele determines the onset and severity of the disease in patients with the N370S mutation. Longer follow-up, bigger cohorts of patients and multicentric studies should be conducted to further define the association between the genotypic and phenotypic expression in GD.

1. Introduction

Gaucher Disease (GD) is a rare autosomal recessive disorder of lipid metabolism and is the most prevalent lysosomal storage disease. There is considerable variability in incidence rate among different populations. The estimated annual incidence in the general population is 1/40,000 to 1/60,000 births, however, it reaches up to 1/800 in Ashkenazi Jews [1].

GD is caused by decreased activity of the lysosomal enzyme β-glucocerebrosidase, which catalyzes the breakdown of the glycolipid glucosylceramide (GlcCer) to ceramide and glucose. β-glucocerebrosidase is a 497 amino acid glycoprotein, encoded by the glucocerebrosidase gene (GBA1), located on chromosome 1 (1q21), which spans 7.6 kb of genomic DNA divided into 11 exons [2]. The majority of GD cases result from pathologic mutations in this gene. According to the Human Genome Mutation Database (HGMD), around 500 mutations have been described up to date, with variable prevalence in different ethnic populations [1].

Molecular heterogeneity of the disease and notable variation in allele distribution among different populations have been noticed. However, four mutations have been observed more frequently, including N370S, IVS2 + 1 + 1G > A, 84GG and L44P, accounting for 95% of the pathogenic alleles in individuals of Ashkenazi Jews. In non-Jewish populations these four mutations account for 50%-60% of the pathogenic alleles [3]. Among these, the N370S mutation is most frequent, and has

* Corresponding author at: Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, University Clinic for Hematology, 1000 Skopje, Republic of North Macedonia.
E-mail addresses: stojanoskiza@t-home.mk (Z. Stojanoski), dr_irina@yahoo.com (I. Panovska-Stavridis).

https://doi.org/10.1016/j.ymgmr.2022.100895
Received 19 May 2022; Received in revised form 28 June 2022; Accepted 29 June 2022
2214-4269/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
been observed with a prevalence of 40% to 45% in Non-Jewish patients with GD and around 70% among Ashkenazi Jews GD patients [4].

The genotype-phenotype correlation in GD has still not been fully defined [5]. However, gathered knowledge has shown that the N370S mutation is associated with an attenuated disease expression, with N370S homozygotes typically presenting with mild symptoms, indolent clinical course and delayed disease onset. On the other hand, certain mutations, such as the L44P mutation, have been associated with neurological involvement and a severe phenotype [6]. In addition, patients with a heterozygous N370S mutation have been reported to have increased risk of developing Parkinsonism, whereas homozygosity for the N370S mutation has been linked with increased risk of monoclonal gammopathy [7].

We present here the clinical and genetic findings of 14 patients with GD type 1 from the Republic of North Macedonia. We report an unexpectedly high prevalence of the N370S mutation and investigate the possible association between genotype and phenotype expression in our GD cohort.

2. Methods

We evaluated 14 adult patients with GD type 1 followed and treated at The University Clinic for Hematology – Skopje. They originate from 7 various regions of the Republic of North Macedonia. Table 1 lists patients’ individual characteristics, initial clinical manifestations, diagnostic procedures and types of therapy. Genetic profiles of these patients are shown in Table 2. Molecular genetic analyses were performed at The Research Centre for Genetic Engineering and Biotechnology at the Macedonian Academy of Sciences and Arts. Various molecular techniques were applied for detection of GBA1 mutations. DNA was extracted from EDTA peripheral blood mononuclear cells. In most cases, Gaucher Disease Strip Assay (ViennaLab Diagnostics GmbH, Vienna, Austria) was used for screening and detection of the most common mutations (N303S, IVS2+1G>A, 84GG, L44P, D409H, V394L, R463C and R496H) and the two most common recombinant alleles RecNciI, RecTL, following the manufacturer protocol. The assay is based on Polymerase Chain reaction (PCR) amplification and reverse hybridization of the amplification (biotinylated) PCR products to a strip containing allele-specific oligonucleotide probes. Affected alleles were detected by streptavidin-alkaline phosphatase and color substrates and identified as homozygotes, heterozygotes, and normal genotypes. DNA Sequencing (Sanger Method), followed by automated system capillary electrophoresis was applied for detection of point mutations in GBA gene exons, while Multiplex ligation probe amplification analysis with subsequent capillary electrophoresis was used for deletions and larger duplications in the exons. Samples that were not completely characterized by this approach were further analyzed by Next Generation Sequencing (NGS).

3. Results

3.1. Demographic characteristics

The study group consisted of 14 adult patients. There were 8 females and 6 males. The mean age of the patients was 39 (range: 19–55), while the mean age at the time of diagnosis was 30 (range 4–53). All patients were born to non-consanguineous marriages. Four patients were of ethnic Macedonian origin and 10 of Albanian ethnicity. Criteria for ethnic affiliation were based on personal identification of the patients. There were 3 relationships of first degree: patients 2 and 3; 7 and 8 and 9 and 10 (brother-sister; brother-brother and sister-sister respectively). There were no other interpersonal relationships and family linkages in both groups. Based on family history, none of the patients had any Jewish ancestry.

Six patients were diagnosed with GD in childhood (mean age 9; range: 4–14) at the University Clinic for Pediatric Diseases and later referred to our institution. The remaining seven were diagnosed in adulthood at our institution (mean age 43; range: 37–53).

3.2. Clinical and hematological findings

All patients, in whom enzyme replacement therapy (ERT) was initiated before puberty, have reached expected mid-parental height. In addition, all of them have normal body mass index (BMI). Majority of the patients diagnosed in adulthood (62%) have normal BMI. Females in this group are of short stature with an average height of 154.5 cm, which

| No | Sex | Ethnicity | Age at presentation | Diagnostic procedure | Treatment |
|----|-----|-----------|---------------------|----------------------|-----------|
| 1  | F   | Albanian  | 11                  | Genetic analysis; BMB| Imiglucerase|
| 2**| M   | Albanian  | 4                   | Genetic analysis; enzyme assay, BMB| Splenectomy|
| 3**| F   | Albanian  | 8                   | Genetic analysis; enzyme assay, BMB| Imiglucerase|
| 4  | M   | Albanian  | 7                   | Genetic analysis; enzyme assay, BMB| Splenectomy|
| 5  | M   | Albanian  | 44                  | Genetic analysis; BMB | Splenectomy|
| 6  | F   | Macedonian| 37                  | Genetic analysis; enzyme assay, BMB| Splenectomy|
| 7**| M   | Macedonian| 37                  | Genetic analysis; BMB | Splenectomy|
| 8**| M   | Macedonian| 14                  | Genetic analysis; BMB | Taliglucerase alfa|
| 9**| F   | Albanian  | 46                  | Genetic analysis; BMB | Taliglucerase alfa|
| 10**|F  | Albanian  | 42                  | Genetic analysis; BMB | Velaglucerase alfa|
| 11 | F   | Albanian  | 41                  | Genetic analysis; BMB | Taliglucerase alfa|
| 12 | M   | Albanian  | 47                  | Genetic analysis; BMB | Splenectomy|
| 13 | F   | Macedonian| 53                  | Genetic analysis; Bone biopsy | Taliglucerase alfa|
| 14 | F   | Albanian  | 37                  | Genetic analysis; Bone biopsy | Velaglucerase alfa|

Legend: BMB - bone marrow biopsy, F-female, M-male.
** Patients number 2&3; 7&8 and 9&10 are siblings.
is not the case with male individuals. The most frequent clinical finding was splenomegaly. Massive splenomegaly, defined as spleen reaching more than 15 cm in diameter on abdominal ultrasonography, was present in 6 patients. Four of them underwent splenectomy at the age of 5, 7, 40 and 6, respectively (Table 1). Concomitant hepatomegaly was found in 7 patients. The most common laboratory abnormality was thrombocytopenia, which was moderate in 8 patients (platelet counts of 50 to 100 × 10^9/L) and severe in one patient (platelet counts below 50 × 10^9/L). Anemia was documented in 7 patients. We found a high prevalence of bone pathology in our patients. All but one of the patients diagnosed in adulthood had osteoporosis or severe osteopenia, assessed by bone densitometry. Bone fractures were confirmed in six patients - one patient had a pathological rib fracture as a child; five adults had hip fractures and two of them underwent total hip endoprosthesis implantation due to extensive hip arthritis.

### 3.2.1. Neurological status

All our patients were considered to have a non-neuropathic disease-GD type 1, based on the absence of neurological complications associated with abnormal accumulation of glucocerebroside in the brain. However, emerging scientific reports indicating increased incidence of Parkinsonism and peripheral neuropathies in patients with type 1 disease question the suitability of the conventional classification and many authors consider GD as a continuum of phenotypes [8]. Therefore, our patients were evaluated for the presence of neurological symptoms or signs that could be present in GD type 1 such as Parkinsonism, peripheral neuropathies, abnormal eye movements and psychiatric symptoms [9,10]. By the time of the follow-up, only one patient who carries the D399N mutation had peripheral motor neuropathy on both legs, which was secondary to the marked bone disease and deformities of the legs. He also experienced hip fractures on several occasions and suffered from anoxia.

### 3.3. Molecular genetic analyses

Genetic analysis identified 6 different mutations that were distributed in 6 different genotypes. The N370S mutation was most frequent and was identified in 17/28 alleles (60.7%). Other frequent mutations included the 1263del55 frameshift deletion and a double mutant allele of two in cis missense mutations (H255Q/D409H), which were both detected in 4/28 alleles. The IVS + 1G > A mutation, which has been detected at a relatively high frequency in other populations, was detected in 1/28 alleles. The remaining two mutations included D399N and W92*, and were also detected in one allele each.

One Macedonian origin was a homozygote for N370S and three patients were compound heterozygotes for N370S and IVS + 1G > A (one patient) or 1263del55 – (two brothers). We found 5 different mutations and 5 different genotypes in patients of Albanian origin, including N370S/N370S, N370S/D438N, H255Q/D409H/N370S, W92*/N370S and N370S/D399N.

The most common genotypes were N370S/1263del55 and H255Q/D409H/N370S, each accounting for 28.6% (4/14 patients), followed by the N370S homozygosity (3/14 patients). The IVS + 1G > A/N370S; W92*/N370S and N370S/D438N genotypes were present in one patient each (1/14).

### 3.4. Genotype-phenotype correlations

Data on genotype-phenotype correlations are presented in Table 3. One of the patients with N370S homozygosity was diagnosed as a child presenting with hepatosplenomegaly, bone pains and rib fractures. The other two patients were sisters and were both diagnosed at an age of >40. They had a similar clinical presentation, including splenomegaly, moderate thrombocytopenia and anemia, but in contrast to patients with compound N370S heterozygosity had only mild bone pathology (osteopenia without osteoporosis and pathological fractures).

Among patients harboring the N370S/1263del55 genotype, the first two patients were diagnosed at the age of 4 and 8, respectively, presenting with hepatosplenomegaly. These two patients had been placed on enzyme replacement therapy (ERT) and had no signs of bone disease. In contrast, the most dominant feature in the other two patients, both diagnosed in adulthood was severe bone disease.

All compound heterozygotes for N370S and H255Q/D409H were diagnosed at adult age with advanced bone disease and pathological fractures. Three of them presented with massive splenomegaly and cytopenia. The patient carrying the W92* mutation was diagnosed at the age of 11 with organomegaly and thrombocytopenia. ERT was promptly initiated and she had normal hematological parameters and no signs of organomegaly at presentation in our institution. The patient carrying D399N, who was also diagnosed with GD as a child, due to poor compliance was irregularly monitored and treated.

### 4. Discussion

GD is considered to be an underdiagnosed disease due to the variable symptomatology and the lack of specialized referral centers. Approximately one in six patients reports a diagnosis delay of seven years from the first symptoms.
the first medical consultation [11]. Assuming an annual birth rate of 19,000 (State Statistical Office of Republic of North Macedonia), we expect an annual incidence rate of GD in our population of 0.31–0.47. We have data for a total of 20 diagnosed patients with GD type 1. There is anecdotal data for 2–3 suspected type 3 GD patients before the year of 2000, which were never confirmed, and no medical documentation is available. All adult patients had no or mild symptomatology at a younger age and symptoms developed after the third decade of life. As described above, our patients manifested various degrees of haematological and skeletal involvement. Our results are in line with the results from a large survey from 11 international centers [11], that reported splenomegaly, associated with hepatomegaly and thrombocytopenia as the most common presenting feature, occurring in 60% of 668 patients; followed by anemia (40%) and bone pains (50%).

We compared our molecular findings with the studies from neighboring and other European countries. N370S is present at a higher prevalence (60.7%) in our population compared to other countries in the Balkans or among Albanian descendants in the Adriatic area of Italy [21].

Our analysis uncovered two rare mutations, W92* and D399N. The W92* or c.392A > G (p.Trp131Ter) mutation results in a premature termination codon and consequent truncation or absence of the encoded protein due to nonsense mediated decay. Several mutations in the same codon have been described. It is shown to be a pathogenic mutation, but data on its clinical implication are scarce [10,16,22]. In our patient, a young girl of Albanian ethnicity, the presence of this mutation resulted in massive splenomegaly and hepatomegaly, accompanied by cytopenia.

The D399N or c.1312G > A (p.Asp438Asn) missense mutation is located in the catalytic domain and has been reported to decrease the GBA enzymatic activity [23]. This mutation has been identified in only a few patients and data on its clinical significance in type 1 GD are lacking. It was described in a GD type 2 in association with L444P in a stillborn baby, and later in a heterozygous status with R463C mutation in a 24-year-old girl with organomegaly, bone disease and abnormal eye movements [24]. Previous data on the association of the missense substitutions in proximity with congenital heart disease expose the probable severity of this variant [10]. However, our patient had no evidence of cardiac disease, neither primary neurological and ocular involvement.

5. Conclusions

This is the first comprehensive overview of the molecular genetics and clinical phenotype of patients diagnosed with GD type 1 from the Republic of North Macedonia. The majority of detected mutations are well described variants, but our analyses detected two rare variants, whose clinical significance should be further studied. Our analysis revealed an unexpectedly high prevalence of the N370S allele. Patients with this mutation had relatively mild symptoms and no neurological involvement, consistent with an attenuated disease expression. A high degree of phenotypic heterogeneity was observed, suggesting that the other allele also influences the clinical course of patients with the N370S mutation. To better clarify the phenotypic consequences of specific mutations, other than N370S, and to further investigate the genotype/phenotype correlation in type 1 GD patients, data on larger GD populations would be required. Multicentre genotype/phenotype studies should be encouraged.

Funding

The authors declare that they have no financial compensation or other kind of support and funding.
Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding authors on demand.

Author contributions

Conceptualization: Irina Panovska-Stavridis*, Nevenka Ridova*. Data curation: Irina Panovska-Stavridis, Nevenka Ridova, Sanja Trajkova, Biljana Chonevska, Zlate Stojanoski, Martin Ivanovski, Marija Popova-Labachevska, Simona Stojanoska-Jakimovska, Venko Filipche, Aspazija Sofijanova. Writing: Nevenka Ridova* and Irina Panovska-Stavridis*. Data curation: Irina Panovska-Stavridis, Nevenka Ridova, Sanja Trajkova, Biljana Chonevska, Zlate Stojanoski, Martin Ivanovski, Marija Popova-Labachevska, Simona Stojanoska-Jakimovska, Venko Filipche, Aspazija Sofijanova. Supervision: Irina Panovska-Stavridis. Formal analysis: Irina Panovska-Stavridis, Nevenka Ridova, Martin Ivanovski.

Ethics approval

Not required.

Patient consent for publication

Informed consent was obtained from all patients for being included in the study.

Declaration of Competing Interest

The authors declare that they have no conflict of interest. All authors have provided ICMJE disclosure forms.

Data availability

Data will be made available on request.

Acknowledgements

To the representative office of the company Pfizer Inc. in Belgrade, Serbia for providing the funding for performing genetic analysis.

References

[1] J. Stümpen, N. Belmatoug, F. Camou, et al., A review of Gaucher disease pathophysiology, clinical presentation and treatments, Int. J. Mol. Sci. 18 (2) (2017) 441.
[2] E. Beutler, T. Gelbart, Glucocerebrosidase (Gaucher disease), Hum. Mutat. 8 (1996) 207–215.
[3] G.M. Pastore, D.A. Hughes, Gaucher disease. 2000 Jul 27 [Updated 2018 Jun 21], in: M.P. Adam, H.H. Ardinger, R.A. Pagon (Eds.), GeneReviews® [Internet], University of Washington, Seattle, Seattle (WA), 1993-2020.
[4] A. Díaz, M. Montfort, B. Cormand, et al., Gaucher disease: the N370S mutation in Ashkenazi Jewish and Spanish patients has a common origin and arose several thousand years ago, Am. J. Hum. Genet. 64 (4) (1999 Apr) 1233-1238.
[5] J. Charron, H.C. Andersson, P. Kaplan, et al., The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease, Arch. Intern. Med. 160 (18) (2000) 2835–2843.
[6] G.A. Grabowski, Gaucher disease: gene frequencies and genotype/phenotype correlations, Genet. Test. 1 (1) (1997) 5–12.
[7] E. Sidransky, M.A. Nalls, J.O. Astry, et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease, N. Engl. J. Med. 361 (2009) 1651–1661.
[8] E. Sidransky, Gaucher disease: complexity in a “simple” disorder, Mol. Genet. Metab. 83 (1–2) (2004 Sep-Oct) 6–15.
[9] P. Cherin, C. Rose, C. de Roux-Serratrices, D. Tardy, et al., The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FORG), J. Inherit. Metab. Dis. 33 (3) (2010 Aug) 331–338.
[10] M. Biegstraaten, I.N. van Schaik, J.M. Aerts, C.E. Hollok, ‘Non-neuropathonic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature, J. Inherit. Metab. Dis. 31 (3) (2008 Jun) 337–349.
[11] A. Mehta, N. Belmatoug, B. Bembi, et al., Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians, Mol. Genet. Metab. 122 (3) (2017) 122–129.
[12] Virtut Velmishi, Clinical and diagnostic findings of 19 Gaucher patients in Albania, J. Liver 02 (2013), https://doi.org/10.4172/2167-0889.1000122.
[13] C. Drugan, L. Procopciuc, G. Jebeleanu, et al., Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations, Eur. J. Hum. Genet. 10 (2002) 511–515.
[14] M. Erdos, K. Hodanova, S. Taskö, et al., Genetic and clinical features of patients with Gaucher disease in Hungary, Blood Cells Mol. Dis. 39 (1) (2007) 119–123.
[15] E. Dimitriou, M. Moraitou, M. Cozar, et al., Gaucher disease: biochemical and molecular findings in 141 patients diagnosed in Greece, Mol. Genet. Metab. Rep. 24 (2020 Jun 7) 100614.
[16] Gizem Oral, Ersin Gümüş, Hülya Demir, Ayse Yuce, Emre (Dökmeci), Serap, Molecular genetic analysis of Turkish Gaucher’s disease patients reveals three novel variants in Glucocerebrosidase (GBA) gene, Meta Gene 25 (2020) 1012725, https://doi.org/10.1016/j.mgene.2020.100725. In this issue, ISSN: 2241-5400.
[17] M.A. Torralba, P. Alfonso, J.J. Pérez-Calvo, et al., High prevalence of the 55-bp deletion (c.1263del55) in exon 9 of the glucocerebrosidase gene causing misdagnosis (for homozygous N370S (c.1226A>G) mutation) in Spanish Gaucher disease patients, Blood Cells Mol. Dis. 29 (1) (2002) 35–40.
[18] J. Vitayashthil, G. Gibney, A.D. Baxevanis, B.K. Stubblefield, E. Sidransky, N. Tayebi, Glucocerebrosidase mutation H255Q appears to be exclusively in cis with D409H: structural implications, Clin. Genet. 75 (5) (2009) 503–504.
[19] M. Filocamo, S. Grossi, M. Stroppiano, P. Tortori-Donati, S. Regis, A. Allegri, M. Di Rocco, Homozygosity for a non-psychedelic complex glucocerebrosidase allele as cause of an atypical neuropathonic form of Gaucher disease, Am. J. Med. Genet. A 134A (1) (2005 Apr 1) 95–96.
[20] H. Michelakakis, M. Moraitou, E. Dimitriou, et al., Homozygosity for the double D409H+H255Q allele in type II Gaucher disease, J. Inherit. Metab. Dis. 29 (4) (2006 Aug) 591.
[21] Raul Santamaría, Helen Michelakakis, et al., Haplotype analysis suggests a single Balkan origin for the Gaucher disease [D409H1255Q] double mutant allele, Hum. Mutat. 29 (2022) E58–E67, https://doi.org/10.1002/humu.20776.
[22] M.E. Grace, R.J. Desnick, G.M. Pastores, Identification and expression of acid beta-gluco-lactonase mutations causing severe type 1 and neuropathologic type 2 Gaucher disease in non-Jewish patients, J. Clin. Invest. 99 (10) (1997) 2530–2537.
[23] B. Liu, A. Kazimiürzuk, M. Zhang, C.R. Scott, R.S. Hegde, G.A. Grabowski, Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations, J. Biol. Chem. 281 (7) (2006 Feb 17) 4242–4253.
[24] N. Tayebi, J. Herman, E.I. Ginns, E. Sidransky, Genotype D399N/R463C in a patient with type 3 Gaucher disease previously assigned genotype N370S/R463C, Biochem. Mol. Med. 57 (2) (1996 Apr) 149–151.